---
name: aria-briefing
description: >
  Comprehensive regulatory briefing report generation skill.
  Synthesizes all pipeline data into executive-ready documents.
  Use for comprehensive reports integrating determination, classification, pathway, estimates, and plan.
allowed-tools: Read Grep Glob ToolSearch
user-invocable: false
metadata:
  version: "1.0.1"
  category: "domain"
  status: "active"
  updated: "2026-02-11"
  modularized: "false"
  tags: "briefing, executive-summary, comprehensive-report, pipeline-integration"
  knowledge-base-date: "2026-01"

# MoAI Extension: Progressive Disclosure
progressive_disclosure:
  enabled: true
  level1_tokens: 100
  level2_tokens: 2500

# MoAI Extension: Triggers
triggers:
  keywords: ["briefing", "brief", "executive summary", "comprehensive report", "regulatory summary"]
  phases: ["run"]
---

# Regulatory Briefing Report Generation Skill

## Quick Reference

**Purpose**: Generate comprehensive regulatory briefing reports synthesizing all available pipeline data into executive-ready documents.

**Input**: All .aria/ pipeline data (determination, classification, pathway, estimation, plan, comparison), optional focus area
**Output**: Executive briefing with summary, detailed analysis, recommendations, and appendices
**Knowledge Base Date**: 2026-01

---

## Decision Framework

### Briefing Report Structure

#### Executive Summary (1-2 pages)
- **Product Overview**: Device name, intended use, regulatory scope
- **Regulatory Status**: Device determination, classification across regions
- **Recommended Pathway**: FDA, EU MDR, MFDS submission routes
- **Timeline & Cost**: Overall project estimate (expected timeline, budget range)
- **Key Risks**: Critical regulatory challenges with traffic light assessment
- **Strategic Recommendations**: Top 3 action items for leadership

#### Detailed Analysis (per pipeline step)
1. **Device Determination**: Medical device status per region, applicable regulations
2. **Classification**: Class/Grade assignment per region with rationale
3. **Regulatory Pathways**: Submission routes, timelines, requirements
4. **Cost & Timeline Estimates**: Budget breakdown, milestone schedule
5. **Regulatory Plan**: Phase-by-phase implementation roadmap
6. **Multi-Country Comparison**: Regional requirement differences (if available)

#### Recommendations Section
- **Immediate Actions**: Tasks for next 30 days
- **Critical Dependencies**: Key decision points and blockers
- **Resource Requirements**: Personnel, consultants, testing facilities
- **Risk Mitigation**: Strategies for identified regulatory challenges

#### Appendices
- **Regulatory Citations**: All referenced regulations (FDA CFR, EU MDR Articles, MFDS ì˜ë£Œê¸°ê¸°ë²•)
- **Data Sources**: Attribution for all information used
- **Escalation Items**: Items requiring expert review with rationale
- **Glossary**: Regulatory terms and acronyms

---

## Workflow

### Step 1: Load All Available Pipeline Data

Scan `.aria/products/<product-name>/<date>/` for:
- `determination.summary.md` (device status)
- `classification.summary.md` (class/grade)
- `pathway.summary.md` (submission routes)
- `estimation.summary.md` (cost/timeline)
- `plan.summary.md` (milestone roadmap)
- `comparison.summary.md` (multi-country analysis, optional)

**Priority for Briefing**:
- Use `.summary.md` files for executive summary (compressed context)
- Use full `.md` files for detailed analysis section (complete information)

### Step 2: Assess Data Completeness

Categorize pipeline completeness:

**Full Pipeline** (all 5 core steps available):
- determination â†’ classification â†’ pathway â†’ estimation â†’ plan
- Generate comprehensive briefing with all sections

**Partial Pipeline** (some steps available):
- Generate briefing covering available data
- Indicate missing steps with recommendations to complete

**Minimal Data** (only determination or classification):
- Generate focused briefing on available analysis
- Strong recommendations to execute remaining pipeline steps

### Step 3: Identify Focus Area (Optional)

If user specifies focus area:
- **Clinical Strategy**: Emphasize clinical evidence requirements, trial planning
- **Cost Control**: Emphasize budget optimization, cost reduction opportunities
- **Timeline Acceleration**: Emphasize parallel submission, expedited pathways
- **Multi-Market Entry**: Emphasize comparison analysis, harmonization strategy

Apply focus area weighting in recommendations and executive summary.

### Step 4: Synthesize Executive Summary

Extract key information from all loaded summaries:

**From Determination Summary**:
- Medical device status (YES/NO/CONDITIONAL)
- Applicable regions (FDA, EU MDR, MFDS)

**From Classification Summary**:
- FDA Class (I/II/III)
- EU MDR Class (I/IIa/IIb/III)
- MFDS Grade (1/2/3/4)
- Overall risk profile

**From Pathway Summary**:
- Recommended pathways per region
- Critical path (longest timeline)

**From Estimation Summary**:
- Total budget range (optimistic/expected/pessimistic)
- Total timeline (end-to-end)

**From Plan Summary**:
- Number of phases
- Key milestones and dependencies

**From Comparison Summary** (if available):
- Harmonization strategy
- Key regulatory differences

### Step 5: Generate Detailed Analysis

For each pipeline step with full data available:
- Load full `.md` file content
- Extract: Input, Analysis, Traffic Light, Escalation, Sources
- Present in structured format with subsections

### Step 6: Formulate Recommendations

Based on synthesized data:

**Immediate Actions** (next 30 days):
1. [Action based on current pipeline stage]
2. [Critical dependency resolution]
3. [Expert consultation if escalation flagged]

**Critical Dependencies**:
- [Key decision points from plan]
- [Data gaps requiring resolution]
- [External dependencies (testing, clinical, notified body)]

**Resource Requirements**:
- Regulatory consultants (FDA/EU/MFDS expertise)
- Testing facilities (per pathway requirements)
- Clinical trial sites (if PMA or Class III pathway)
- Notified Body (if EU Class IIa+)

**Risk Mitigation**:
- [Strategies for YELLOW/RED traffic light items]
- [Contingency plans for identified risks]

### Step 7: Assign Overall Traffic Light

Aggregate traffic lights from all pipeline steps:

- **ğŸŸ¢ GREEN**: All steps GREEN, low-risk regulatory path
- **ğŸŸ¡ YELLOW**: Any step YELLOW or RED, moderate-high risk, expert review recommended
- **ğŸ”´ RED**: Multiple RED flags, significant regulatory barriers, fundamental approach change needed

### Step 8: Generate Output (ER-017 Two-Phase Approach)

**Phase A - Analysis Turn** (Present key findings for user confirmation):

```markdown
# ê·œì œ ë¸Œë¦¬í•‘ ë¶„ì„ ê²°ê³¼ (ìš”ì•½)

## ì œí’ˆ ê°œìš”
- **ì œí’ˆëª…**: [Product Name]
- **ì˜ë£Œê¸°ê¸° í•´ë‹¹ ì—¬ë¶€**: [YES/NO/CONDITIONAL]
- **ë¶„ë¥˜**: FDA Class [I/II/III], EU MDR Class [I/IIa/IIb/III], MFDS Grade [1/2/3/4]

## í•µì‹¬ ë°œê²¬ì‚¬í•­
1. **ê·œì œ ê²½ë¡œ**: [FDA Pathway] / [EU Pathway] / [MFDS Pathway]
2. **ì˜ˆìƒ ì†Œìš” ê¸°ê°„**: [Critical Path Timeline]
3. **ì˜ˆìƒ ë¹„ìš©**: [Budget Range]
4. **ì£¼ìš” ìœ„í—˜**: [Key risks with traffic light]

## ê¶Œì¥ì‚¬í•­ (Top 3)
1. [Immediate action 1]
2. [Immediate action 2]
3. [Immediate action 3]

## ì „ì²´ ìœ„í—˜ë„ í‰ê°€
- **Traffic Light**: [ğŸŸ¢ GREEN / ğŸŸ¡ YELLOW / ğŸ”´ RED]

[If YELLOW or RED]: **âš ï¸ ì „ë¬¸ê°€ ê²€í†  ê¶Œì¥**: ë³µì¡ë„ê°€ ë†’ì€ ê·œì œ ê²½ë¡œì´ë¯€ë¡œ ê·œì œ ì „ë¬¸ê°€ì™€ ìƒë‹´ì„ ê¶Œì¥í•©ë‹ˆë‹¤.

---
**ì‚¬ìš©ì í™•ì¸ í•„ìš”**: ìœ„ ë¶„ì„ ë‚´ìš©ì„ ê²€í† í•˜ì‹  í›„, ì „ì²´ ë³´ê³ ì„œ ìƒì„±ì„ ì§„í–‰í•˜ì‹œê² ìŠµë‹ˆê¹Œ?
```

**Phase B - Full Report Generation** (After user confirmation, generate complete briefing):

```markdown
# ê·œì œ ë¸Œë¦¬í•‘ ë³´ê³ ì„œ

## ëª©ì°¨
1. [ê²½ì˜ì§„ ìš”ì•½ (Executive Summary)](#ê²½ì˜ì§„-ìš”ì•½)
2. [ìƒì„¸ ë¶„ì„ (Detailed Analysis)](#ìƒì„¸-ë¶„ì„)
3. [ê¶Œì¥ì‚¬í•­ (Recommendations)](#ê¶Œì¥ì‚¬í•­)
4. [ë¶€ë¡ (Appendices)](#ë¶€ë¡)

---

## ê²½ì˜ì§„ ìš”ì•½

### ì œí’ˆ ê°œìš”
- **ì œí’ˆëª…**: [Product Name]
- **ì˜ë„ëœ ìš©ë„**: [Intended Use]
- **ê·œì œ ë²”ìœ„**: FDA (ë¯¸êµ­), EU MDR (ìœ ëŸ½), MFDS (í•œêµ­)

### ê·œì œ í˜„í™©
- **ì˜ë£Œê¸°ê¸° í•´ë‹¹ ì—¬ë¶€**: [YES/NO/CONDITIONAL] ([Traffic Light])
- **ë¶„ë¥˜ ë“±ê¸‰**:
  - FDA: Class [I/II/III]
  - EU MDR: Class [I/IIa/IIb/III]
  - MFDS: Grade [1/2/3/4]

### ê¶Œì¥ ê²½ë¡œ
- **FDA**: [Pathway] (ì˜ˆìƒ ì†Œìš” ê¸°ê°„: [Timeline])
- **EU MDR**: [Pathway] (ì˜ˆìƒ ì†Œìš” ê¸°ê°„: [Timeline])
- **MFDS**: [Pathway] (ì˜ˆìƒ ì†Œìš” ê¸°ê°„: [Timeline])
- **Critical Path**: [Region] ([Longest Timeline])

### ë¹„ìš© ë° ì¼ì •
- **ì´ ì˜ˆìƒ ë¹„ìš©**: [Optimistic] ~ [Expected] ~ [Pessimistic]
- **ì´ ì˜ˆìƒ ê¸°ê°„**: [End-to-end Timeline]
- **ì£¼ìš” ë§ˆì¼ìŠ¤í†¤**: [Key milestones from plan]

### ì£¼ìš” ìœ„í—˜
1. [Risk 1 with traffic light]
2. [Risk 2 with traffic light]
3. [Risk 3 with traffic light]

### ì „ëµ ê¶Œì¥ì‚¬í•­
1. [Top recommendation 1]
2. [Top recommendation 2]
3. [Top recommendation 3]

---

## ìƒì„¸ ë¶„ì„

### 1. ì˜ë£Œê¸°ê¸° íŒì • (Device Determination)
[Full determination analysis from determination.md]

### 2. ë“±ê¸‰ ë¶„ë¥˜ (Classification)
[Full classification analysis from classification.md]

### 3. ê·œì œ ê²½ë¡œ (Regulatory Pathways)
[Full pathway analysis from pathway.md]

### 4. ë¹„ìš© ë° ì¼ì • ì¶”ì • (Cost & Timeline Estimation)
[Full estimation analysis from estimation.md]

### 5. ê·œì œ ê³„íš (Regulatory Plan)
[Full plan analysis from plan.md]

### 6. ë‹¤êµ­ê°€ ê·œì œ ë¹„êµ (Multi-Country Comparison)
[Full comparison analysis from comparison.md if available]
[If not available: "ë‹¤êµ­ê°€ ë¹„êµ ë¶„ì„ì€ ìˆ˜í–‰ë˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. `/aria:compare` ëª…ë ¹ìœ¼ë¡œ ìˆ˜í–‰ ê°€ëŠ¥í•©ë‹ˆë‹¤."]

---

## ê¶Œì¥ì‚¬í•­

### ì¦‰ì‹œ ì‹¤í–‰ í•­ëª© (30ì¼ ì´ë‚´)
1. [Immediate action 1 with rationale]
2. [Immediate action 2 with rationale]
3. [Immediate action 3 with rationale]

### í•µì‹¬ ì˜ì¡´ì„±
- [Critical dependency 1]
- [Critical dependency 2]
- [Critical dependency 3]

### í•„ìš” ë¦¬ì†ŒìŠ¤
- **ê·œì œ ì „ë¬¸ê°€**: FDA/EU MDR/MFDS ì „ë¬¸ ì»¨ì„¤í„´íŠ¸
- **ì‹œí—˜ ê¸°ê´€**: [Testing requirements per pathway]
- **ì„ìƒ ì‹œí—˜**: [Clinical trial requirements if applicable]
- **ì¸ì¦ ê¸°ê´€**: [Notified Body if EU Class IIa+]

### ìœ„í—˜ ì™„í™” ì „ëµ
- [Risk mitigation strategy 1]
- [Risk mitigation strategy 2]
- [Risk mitigation strategy 3]

---

## ë¶€ë¡

### A. ê·œì œ ê·¼ê±° (Regulatory Citations)
- **FDA**: [FDA CFR citations from all steps]
- **EU MDR**: [EU MDR Article citations from all steps]
- **MFDS**: [MFDS ì˜ë£Œê¸°ê¸°ë²• citations from all steps]

### B. ë°ì´í„° ì¶œì²˜ (Data Sources)
- [Attribution summary from all pipeline steps]
- Built-in knowledge: FDA, EU MDR, MFDS decision frameworks (2026-01 knowledge base)
- External sources: [Notion DB / Context7 if used]

### C. ì „ë¬¸ê°€ ê²€í†  í•„ìš” í•­ëª© (Escalation Items)
[All escalation items from pipeline steps with rationale]

### D. ìš©ì–´ì§‘ (Glossary)
- **510(k)**: FDA Premarket Notification
- **PMA**: FDA Premarket Approval
- **CE Marking**: EU conformity marking
- **Notified Body**: EU conformity assessment body
- **PMCF**: Post-Market Clinical Follow-up
- **QMS**: Quality Management System
- [Additional regulatory terms as needed]

---

## ë©´ì±… ì¡°í•­
âš ï¸ **ë³¸ ë¸Œë¦¬í•‘ ë³´ê³ ì„œëŠ” ì°¸ê³  ì •ë³´ì´ë©°, ê·œì œ ìë¬¸ì´ ì•„ë‹™ë‹ˆë‹¤.** ëª¨ë“  ê·œì œ ê²°ì •ì€ ê·œì œ ì „ë¬¸ê°€ì˜ ê²€í† ì™€ ê²€ì¦ì´ í•„ìš”í•˜ë©°, ìµœì¢… ê·œì œ ì œì¶œ ì „ ìµœì‹  ê·œì œ ìš”êµ¬ì‚¬í•­ì„ í™•ì¸í•˜ì‹œê¸° ë°”ëë‹ˆë‹¤.

---
**ìƒì„± ì¼ì‹œ**: [Timestamp]
**ARIA Plugin Version**: 2.0.0
**ë³´ê³ ì„œ ë²„ì „**: [Version if re-generated]
```

### Step 9: Generate Context Simplifier Summary

Create `.summary.md` file:

```markdown
# Briefing Summary

**Product**: [Product Name]
**Date**: [YYYY-MM-DD]

- **Decision**: Comprehensive briefing report generated
- **Pipeline Steps Covered**: [List of available steps]
- **Traffic Light**: [GREEN/YELLOW/RED]
- **Critical Path**: [Region] ([Timeline])
- **Total Budget**: [Expected Range]
- **Key Risks**: [Top 3 risks]
- **Top Recommendations**: [Top 3 actions]
- **Escalation**: [Yes/No with items if yes]
- **Sources**: FDA, EU MDR, MFDS regulations + all pipeline data

---
This summary captures the briefing report for audit trail.
```

---

## Data Source Strategy

1. **Pipeline Data** (Primary): `.summary.md` for executive summary, full `.md` for detailed analysis
2. **Built-in Knowledge** (Supplementary): Briefing structure rules, executive summary framework
3. **External Tools** (Optional): Only when explicitly configured

### Context7 Integration for Regulatory Document Supplementation

**Purpose**: Supplement regulatory citations and verify latest regulatory requirements

**Workflow**:

1. **Tool Discovery**:
   - Use ToolSearch to load Context7 MCP tools: `ToolSearch("context7")`
   - Expected tools: `mcp__context7__resolve-library-id`, `mcp__context7__get-library-docs`

2. **Regulatory Document Supplementation**:
   - When regulatory citations are referenced (FDA CFR, EU MDR, MFDS):
     - Resolve library ID via `mcp__context7__resolve-library-id`
     - Retrieve latest documentation via `mcp__context7__get-library-docs`
     - Cross-reference with built-in knowledge to verify accuracy
     - Attribute Context7 as supplementary source in Appendix B (Data Sources)

3. **Graceful Degradation**:
   - If Context7 unavailable â†’ Use built-in knowledge only
   - Display in Data Source Attribution: "(built-in knowledge, Context7 unavailable)"
   - Briefing remains fully functional without Context7

4. **Source Attribution**:
   - When Context7 used successfully:
     - Appendix B: "External sources: Context7 (regulatory document verification)"
     - Each citation: Add "(verified via Context7 YYYY-MM-DD)" when applicable
   - When Context7 unavailable:
     - Appendix B: "External sources: Context7 (unavailable, built-in knowledge used)"

---

## Traffic Light Definitions

- **ğŸŸ¢ GREEN**: All pipeline steps GREEN, low-risk regulatory path
- **ğŸŸ¡ YELLOW**: Any step YELLOW or RED, moderate-high risk path
- **ğŸ”´ RED**: Multiple RED flags, significant regulatory barriers

---

## Escalation Scenarios

Escalate to regulatory expert when:
- Overall traffic light is YELLOW or RED
- Briefing is for external stakeholders (board, investors, regulatory authorities)
- Critical decision points require executive approval
- Budget or timeline exceeds organizational thresholds

---

## VALID Framework Compliance

- **Verified**: All claims sourced from pipeline data or built-in regulatory knowledge
- **Accurate**: Briefing reflects current pipeline state, all sources attributed
- **Linked**: Cross-references between briefing sections and source pipeline steps
- **Inspectable**: Decision rationale transparent, audit trail via .aria/ files
- **Deliverable**: Output stored in `.aria/products/<product-name>/<date>/briefing.md`

---

## Report Issuance Policy (ER-017)

**Two-Phase Approach**:
1. **Analysis Phase**: Present key findings, traffic light, recommendations for user review
2. **Report Phase**: After user confirmation, generate full formatted report

**Format Options** (via `--format` flag):
- `markdown` (default): Markdown report to `.aria/products/`
- `notion`: Notion page via Notion MCP (requires notion-mcp)
- `gdocs`: Google Docs via Google Drive MCP (requires google-drive-mcp)
- `pdf`: PDF conversion from Markdown (requires pandoc/wkhtmltopdf/weasyprint)

**Google Docs Export Workflow**:

When `--format gdocs` is specified:

1. **Tool Discovery**:
   - Use ToolSearch to load Google Drive MCP tools: `ToolSearch("google drive")`
   - Expected tools: `mcp__gdrive__create_file`, `mcp__gdrive__upload_content`

2. **Graceful Degradation**:
   - If ToolSearch returns no Google Drive tools â†’ Fallback to Markdown
   - Display: "Google Drive MCPê°€ ì„¤ì •ë˜ì§€ ì•Šì•˜ìŠµë‹ˆë‹¤. Markdown í˜•ì‹ìœ¼ë¡œ ë³´ê³ ì„œë¥¼ ìƒì„±í•©ë‹ˆë‹¤."
   - Save to `.aria/products/{product-name}/{date}/briefing.md`
   - Include limitation notice in Data Source Attribution

3. **Google Docs Creation** (if tools available):
   - Generate briefing content in Markdown format first
   - Convert Markdown to Google Docs-compatible format
   - Create document via `mcp__gdrive__create_file`:
     - Title: "{Product Name} - Regulatory Briefing Report ({YYYY-MM-DD})"
     - MimeType: `application/vnd.google-apps.document`
     - Content: Converted briefing content
   - Display Google Docs link to user
   - Save Markdown backup to `.aria/products/{product-name}/{date}/briefing.md`

4. **Error Recovery**:
   - If MCP tool call fails â†’ Fallback to Markdown with error message
   - Error: "Google Driveì— ì—°ê²°í•  ìˆ˜ ì—†ìŠµë‹ˆë‹¤. Markdown í˜•ì‹ìœ¼ë¡œ ë³´ê³ ì„œë¥¼ ìƒì„±í•©ë‹ˆë‹¤."

**User confirmation required before full report generation** (ER-017).

---

## Version History

**v1.0.0** (2026-02-11):
- Initial implementation for Phase 4
- Full pipeline data synthesis
- Executive summary generation
- Detailed analysis per step
- Recommendations and escalation
- Two-phase report issuance (ER-017)
- Multi-format output support
- Context Simplifier integration
- Korean language output
- Traffic light aggregation
- VALID framework compliance

---

**Knowledge Base Cutoff**: 2026-01
**Next Update**: Quarterly regulatory updates
